研究方向：抗癌化合物的设计与机理研究
在读期间及毕业后合作发表论文：
1. Gou Y, Huang GJ, Li JL, Yang F*, Liang H*. Versatile deliverysystems for non-platinum metal-based anticancer therapeutic agents. Coordination Chemistry Reviews, 2021, 441: 213975.
2. Gou Y, Jia XY, Hou LX, Deng JG, Huang GJ, Jiang HW*, Yang F*. Dithiocarbazate−Fe III , −Co III , −Ni II , and −Zn II complexes: design, synthesis, structure, and anticancer evaluation. Journal of Medicinal Chemistry, 2022, 65: 6677−6689.
3. Gou Y, Chen MR, Li SH, Deng JG, Li JL, Fang GH, Yang F*, Huang GJ*. Dithiocarbazate-copper complexes for bioimaging and treatment of pancreaticcancer. Journal of Medicinal Chemistry, 2021, 64: 5485−5499.
4. Gu SS, Yu P, Hu JN, Liu YN, Li ZW, Qian Y, Wang Y, Gou Y*, Yang F*. Mitochondria-localizing N-heterocyclic thiosemicarbazone copper complexes with good cytotoxicity and high antimetastatic activity. European Journal of Medicinal Chemistry, 2019, 164: 654−664.
5. Mo QY, Deng JG, Liu YN, Huang GD, Li ZW, Yu P, Gou Y*, Yang F*. Mixed-ligand Cu(II) hydrazone complexes designed to enhance anticancer activity. European Journal of Medicinal Chemistry, 2018, 156: 368−380.
6. Gou Y, Zhang ZL, Li DY, Zhao L, Cai ML, Sun ZW, Li YP, Zhang Y, Khan H, Sun HB, Wang T*, Liang H*, Yang F*. HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single drug resistance in a breast cancer model. Drug Delivery, 2018, 25: 321−329.
7. Wang J#, Gou Y#, Zhang ZL#, Yu P, Qi JX, Qin QP, Sun HB, Wu XY, Liang H*, Yang F*. Developing an anticancer copper(II) multitarget pro-drug based on the His146 residue in the IB subdomain of modified human serum albumin. Molecular Pharmaceutics, 2018, 15: 2180−2193.
8. Gou Y*, Li JL, Fan BY, Xu BH, Zhou M, Yang F*. Structure and biological properties of mixed-ligand Cu(II) Schiff base complexes as potential anticancer agents. European Journal of Medicinal Chemistry, 2017, 134: 207−217.
9. Gou Y, Zhang Y, Zhang ZL, Wang J, Zhou ZP, Liang H*, Yang F*. Design of an anticancer copper(II) prodrug based on the Lys199 residue of the active targeting human serum albumin nanoparticle carrier. Molecular Pharmaceutics, 2017, 14: 1861−1873.
10. Zhang ZL#, Gou Y#, Wang J#, Yang K, Qi JX, Zhou ZP, Liang SC*, Liang H*, Yang F*. Four copper(II) compounds synthesized by anion regulation: Structure, anticancer function and anticancer mechanism. European Journal of Medicinal Chemistry, 2016, 121: 399−409.
11. Gou Y, Wang J, Chen SF, Zhang Z, Zhang Y, Zhang W, Yang F*. a-N-heterocyclic thiosemicarbazone Fe(III) complex: Characterization of its antitumor activity and identification of anticancer mechanism. European Journal of Medicinal Chemistry, 2016, 123: 354−364.
12. Gou Y, Yang F*, Liang H*. Designing prodrugs based on special residues of human serum albumin. Current Topics in Medicinal Chemistry, 2016, 16: 996−1008.
13. Gou Y, Zhang Y, Qi JX, Chen SF, Zhou ZP, Wu XY, Liang H*, Yang F*. Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer. Oncotarget, 2016, 7: 67004−67019.
14. Gou Y, Qi JX, Ajayi JP, Zhang Y, Zhou ZP, Wu XY, Yang F*, Liang H*. Developing anticancer copper(II) pro-drugs based on the nature of cancer cells and the human serum albumin carrier IIA subdomain. Molecular Pharmaceutics, 2015, 12: 3597−3609.
15. Gou Y, Zhang Z, Qi JX, Liang SC, Zhou ZP, Yang F*, Liang H*. Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin. Journal of Inorganic Biochemistry, 2015, 153: 13−22.
16. Gou Y, Zhang Y, Qi JX, Zhou ZP, Yang F*, Liang H*. Enhancing the copper(II) complexes cytotoxicity to cancer cells through bound to human serum albumin. Journal of Inorganic Biochemistry, 2015, 144: 47−55.
17. Gou Y, Zhang Y, Yang F*, Liang H*. Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs. Current Pharmaceutical Design, 2015, 21: 1848−1861.
18. Gou Y, Zhang Y, Qi J, Kong L, Zhou Z, Liang S, Yang F*, Liang H*. Binding and anticancer properties of plumbagin with human serum albumin. Chemical Biology & Drug Design, 2015, 86: 362−369.
学习经历：
2013/09-2016/06，广西师范大学化学与药学学院(博士)
毕业去向：
毕业后先就职于南通大学，现就职于桂林医学院附属医院呼吸疾病实验室，副研究员
邮箱：sanchuanok@126.com